Adrian Lock - Zomedica Pharmaceuticals GM VP
| ZOM Stock | USD 0.12 0.01 7.69% |
Insider
Adrian Lock is GM VP of Zomedica Pharmaceuticals Corp
| Age | 63 |
| Address | 100 Phoenix Drive, Ann Arbor, MI, United States, 48108 |
| Phone | 734 369 2555 |
| Web | https://www.zomedica.com |
Zomedica Pharmaceuticals Management Efficiency
The company has Return on Asset of (0.0929) % which means that on every $100 spent on assets, it lost $0.0929. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.2392) %, meaning that it generated no profit with money invested by stockholders. Zomedica Pharmaceuticals' management efficiency ratios could be used to measure how well Zomedica Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 11th of December 2024, Return On Tangible Assets is likely to drop to -0.27. In addition to that, Return On Capital Employed is likely to drop to -0.14. At this time, Zomedica Pharmaceuticals' Intangible Assets are very stable compared to the past year. As of the 11th of December 2024, Intangibles To Total Assets is likely to grow to 0.48, while Net Current Asset Value is likely to drop about 113.7 K.Similar Executives
| Showing other executives | INSIDER Age | ||
| Theresa Yanofsky | Canopy Growth Corp | 63 | |
| Eric Dadey | Aquestive Therapeutics | N/A | |
| FCPA FCA | Canopy Growth Corp | 63 | |
| Kevin Gifford | Cronos Group | N/A | |
| Gregory Engel | OrganiGram Holdings | 59 | |
| CPA CPA | OrganiGram Holdings | 55 | |
| CA CBV | Tilray Inc | 52 | |
| Bernard Yeung | Tilray Inc | N/A | |
| Anatoly MD | Shuttle Pharmaceuticals | 80 | |
| Tara Rozalowsky | Canopy Growth Corp | N/A | |
| Ryan Hellard | SNDL Inc | 35 | |
| John Barnet | Aurora Cannabis | N/A | |
| Michael Hoek | Shuttle Pharmaceuticals | 64 | |
| Carlos Cortez | Cronos Group | 51 | |
| Andrew Stordeur | SNDL Inc | 44 | |
| Michael Detlefsen | Aurora Cannabis | 56 | |
| Tyvin MD | Shuttle Pharmaceuticals | 76 | |
| Lance Friedmann | Aurora Cannabis | 65 | |
| Aaron Perlitsh | Lifecore Biomedical | N/A | |
| BSBA Esq | Aquestive Therapeutics | 66 | |
| Albert Bolles | Lifecore Biomedical | 66 | |
Management Performance
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.0929 |
Zomedica Pharmaceuticals Leadership Team
Elected by the shareholders, the Zomedica Pharmaceuticals' board of directors comprises two types of representatives: Zomedica Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zomedica. The board's role is to monitor Zomedica Pharmaceuticals' management team and ensure that shareholders' interests are well served. Zomedica Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zomedica Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Robitaille, Independent Director | ||
| Robert DiMarzo, Consultant | ||
| Rodney Williams, Independent Member | ||
| Robert Cohen, Interim Chief Executive Officer, Director | ||
| Evan Peter, VP Innovation | ||
| Ann Cotter, Interim Chief Financial Officer, Corporate Secretary | ||
| MBA BSBA, Chief Officer | ||
| Johnny Powers, Independent Director | ||
| Adrian Lock, GM VP | ||
| Jane Eagleson, Independent Director | ||
| Angy Guerrant, Director of Portfolio Management | ||
| Ann CPA, Chief Officer | ||
| Mike Zuehlke, Vice Controller | ||
| Shameze Rampertab, Interim Chief Executive Officer, Chief Financial Officer, Executive Director | ||
| Nicole Westfall, VP Marketing | ||
| Jeffrey Rowe, Chairman of the Board | ||
| Christopher MacLeod, Independent Director | ||
| Evan MBA, Vice Innovation | ||
| Larry II, CEO President | ||
| DVM DVM, Consultant | ||
| Anthony Blair, Chief Officer | ||
| Kristin Domanski, Vice Resources | ||
| Angie Moricz, Executive Administrative Assistant | ||
| Nicole MBA, Senior Marketing | ||
| Karen JD, General Secretary | ||
| Greg Blair, Senior Planning | ||
| Russell Klass, Senior Sales | ||
| William MacArthur, Executive Member and Chief Medical Officer, Director of Research and Development | ||
| Stephanie Morley, President, Chief Operating Officer | ||
| Christopher Wolfenberg, Director | ||
| Andrea Eberle, Senior Marketing Manager | ||
| Bruk Herbst, Chief Commercial Officer |
Zomedica Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Zomedica Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.0929 | ||||
| Profit Margin | (2.15) % | ||||
| Operating Margin | (1.48) % | ||||
| Current Valuation | 49.66 M | ||||
| Shares Outstanding | 997.95 M | ||||
| Shares Owned By Insiders | 1.70 % | ||||
| Shares Owned By Institutions | 8.33 % | ||||
| Number Of Shares Shorted | 51.14 M | ||||
| Price To Book | 0.61 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zomedica Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zomedica Pharmaceuticals. If investors know Zomedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zomedica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.06) | Revenue Per Share 0.027 | Quarterly Revenue Growth 0.018 | Return On Assets (0.09) | Return On Equity (0.24) |
The market value of Zomedica Pharmaceuticals is measured differently than its book value, which is the value of Zomedica that is recorded on the company's balance sheet. Investors also form their own opinion of Zomedica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zomedica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zomedica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zomedica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zomedica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zomedica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zomedica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.